Theravance Biopharma Inc TBPH
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if TBPH is a good fit for your portfolio.
News
-
Theravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients with Multiple System Atrophy (MSA) on May 23, 2024
-
Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
-
Theravance Biopharma to Participate in an Upcoming Investor Conference
-
Theravance Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024
-
Theravance Biopharma's stock slides 21% after Phase 4 trial of COPD treatment fails to meet main goal
-
Theravance Biopharma, Mylan Reach Settlement Over Inhalation Drug Yupelri
-
Theravance Says FDA Grants Orphan Drug Designation Status to Ampreloxetine
Trading Information
- Previous Close Price
- $9.45
- Day Range
- $9.40–9.58
- 52-Week Range
- $8.22–11.79
- Bid/Ask
- $9.50 / $9.52
- Market Cap
- $460.83 Mil
- Volume/Avg
- 89,155 / 379,060
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 9.11
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- 43.44%
Company Profile
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 99
- Website
- https://www.theravance.com
Comparables
Valuation
|
Metric
|
TBPH
|
CBAY
|
MORF
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.14 | 12.65 | 1.96 |
Price/Sales | 9.11 | 111.01 | 2,238.41 |
Price/Cash Flow | — | — | — |
Price/Earnings
TBPH
CBAY
MORF
Financial Strength
|
Metric
|
TBPH
|
CBAY
|
MORF
|
|---|---|---|---|
Quick Ratio | 4.84 | 10.70 | 28.43 |
Current Ratio | 5.39 | 10.96 | 28.94 |
Interest Coverage | −23.84 | −5.27 | — |
Quick Ratio
TBPH
CBAY
MORF
Profitability
|
Metric
|
TBPH
|
CBAY
|
MORF
|
|---|---|---|---|
Return on Assets (Normalized) | −4.51% | −30.06% | −19.79% |
Return on Equity (Normalized) | −6.94% | −51.97% | −20.47% |
Return on Invested Capital (Normalized) | −7.84% | −30.87% | −23.98% |
Return on Assets
TBPH
CBAY
MORF
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Psnwhlnr | Hsyg | $557.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Mtpfxxd | Btyfj | $103.3 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Kzlyhgnj | Ljpyhv | $98.8 Bil | |
MRNA
| Moderna Inc | Jntxbmjzx | Kytq | $38.8 Bil | |
ARGX
| argenx SE ADR | Wzrpwqk | Jmcv | $21.3 Bil | |
BNTX
| BioNTech SE ADR | Zyxywmj | Ldb | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Tjzvqmb | Nhsxx | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Ztrrrlsxy | Bnqmtdg | $17.0 Bil | |
RPRX
| Royalty Pharma PLC Class A | Xxcfspscvf | Mmqpwxj | $12.4 Bil | |
INCY
| Incyte Corp | Pqlztwl | Vzggsqp | $11.9 Bil |